Purpose: Recent evidence suggests that reaching the lowest achievable levels of testosterone with androgen deprivation therapy delays disease progression and increases overall survival in men with advanced prostate cancer. The aim of this analysis was to compare posttreatment serum testosterone levels between patients undergoing subcapsular orchiectomy and patients treated with the luteinizing hormone-releasing hormone agonist triptorelin. Materials and Methods: In this randomized clinical trial we included 58 consecutive hormone na€ ıve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015. Followup was 48 weeks. Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections. Androgen status was measured by liquid chromatographytandem mass spectrometry prior to treatment and after 12, 24 and 48 weeks. Between group differences in achieved hormone levels were analyzed by longitudinal Tobit regression. Results: Triptorelin injections resulted in 29% lower testosterone levels (95% CI 17.2e41.7) compared to subcapsular orchiectomy (p <0.001). A significantly higher proportion of men receiving triptorelin had testosterone levels less than 20 ng/dl at 12 and 48 weeks compared to men undergoing orchiectomy (97% vs 79% and 100% vs 87%, respectively, p <0.05). There was no detectable difference in the adrenal androgen reduction between the treatment groups. Conclusions: The use of 24-week depot triptorelin injections results in significantly lower testosterone levels compared to subcapsular orchiectomy. To our Accepted for publication December 1, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
ANDROGEN deprivation therapy has been the key treatment modality for metastatic prostate cancer since its introduction in 1941. Methods of ADT include LHRH agonist and antagonist therapy as well as surgical treatment with bilateral or subcapsular orchiectomy. The aim of ADT is to alleviate prostate cancer related symptoms and reduce the tumor burden by decreasing serum testosterone to levels below 50 ng/dl. 1 Recent studies have suggested that achieving testosterone levels lower than the commonly used threshold of 50 ng/dl delays cancer progression and increases cancer specific and overall survival. 2e5 This has led to a new target level of total testosterone of less than 20 ng/dl. Meanwhile, more accurate methods of testosterone level measurement such as LC-MS/MS 6 have become available, spurring reexamination of the testosterone lowering effect of different ADT methods. In 2012 van der Sluis et al reported thought provoking results showing that LHRH agonist injections lowered testosterone more than surgical castration did in 66 men. 7 The study was limited by a cross-sectional design and a heterogeneous surgical intervention group that included men undergoing sex change operations and men with prostate cancer. Thus, further studies are warranted to retest and reproduce these findings. This is our first planned report of a randomized clinical trial comparing the use of LHRH agonist triptorelin with subcapsular orchiectomy. The primary focus is to compare metabolic complications. The aim of the current analysis was to determine whether posttreatment serum testosterone and adrenal androgen levels differ between the treatment modalities when measured using the accurate method of LC-MS/MS.
MATERIALS AND METHODS

Study Design and Participants
In this analysis of a 2-arm randomized clinical trial the effect of triptorelin 22.5 mg given as a 24-week depot injection on achieved serum testosterone levels with 48-week followup was compared with the effect of subcapsular orchiectomy. Men younger than 90 years with ECOG (Eastern Cooperative Oncology Group) performance status 2 or less, a confirmed diagnosis of prostate cancer without curative treatment options and an indication for receiving ADT were eligible for randomization. Study exclusion criteria were prior androgen therapy, pharmacological treatment for osteoporosis, diabetes mellitus and conditions (eg hemophilia) that substantially increase the risk of surgery as decided by the treating physician.
Allocated treatment began within 14 days of randomization. Randomization was done in 1:1 allocation using a computer generated randomization sequence to which the investigators were blinded. Sequentially numbered, sealed opaque envelopes prepared by a nonaffiliated person were used for treatment allocation. Treatment was not blinded to the investigators after allocation.
Participants allocated to the triptorelin arm were treated with the antiandrogen bicalutamide 50 mg daily for 30 days upon first injection. Participants received no other treatments during the trial that could interfere with the gonadal axis.
The trial was performed in accordance with the Declaration of Helsinki and the legal regulations in Denmark. Permission was obtained from the Danish Medicines Agency (EudraCT 2013-002553-29 and registered on www.clinicaltrialsregister.eu) and the Capital Regional Committee on Health Research Ethics in Denmark (H-2-2013-107). All patients provided oral and written consent prior to study inclusion.
Data Collection
Participants were evaluated at baseline before treatment, and 12, 24 and 48 weeks after the first injection or surgery. Venous blood samples for hormonal measurements were collected between 8 and 9 a.m. All participants fasted a minimum of 8 hours prior to each visit. BMI was calculated from height via a mounted stadiometer and weight using a WB-110MA scale (Tanita, Tokyo, Japan).
Hormone Analyses
Serum total testosterone (NRR 242 to 732 ng/dl), androstenedione (NRR 1.6 to 6.5 nmol/l), DHEAS (NRR 700 to 7,000 nmol/l) and 17-hydroxyprogesterone (NRR less than 8 nmol/l) were measured by LC-MS/MS using an Acquity UPLC XevoÔ TQ MS device. Testosterone levels are reported in nmol/l and were converted to ng/dl by dividing by 0.0347.
The interassay CV for serum total testosterone was 6.7% at 24.7 ng/dl and 20.5% at 5.7 ng/dl. For testosterone a lower reporting LRL of 8.6 ng/dl was determined at the laboratory. The interassay CV of androstenedione, DHEAS and 17-hydroxyprogesterone was 10.7% at 0.734 nmol/l, 9.1% at 298.7 nmol/l, and 7.5% and 21.3% at 1.552 and 0.367 nmol/l, respectively. The LRL of androstenedione, DHEAS and 17-hydroxyprogesterone was 1.0, 100 and 1.0 nmol/l, respectively.
SHBG was analyzed by a sandwich chemiluminescence based immunoassay (Siemens, Munich, Germany) with a CV of less than 7.0%. Estradiol (NRR less than 0.146 nmol/l) was measured using the ADVIA CentaurÒ chemiluminescence based competitive immunoassay. The CV at 0.125 nmol/l was 12.0%. LH (NRR 1.5 to 9.3 IU/l) and FSH (NRR 1.4 to 18.1 IU/l) were measured with the 2-site ADVIA Centaur sandwich chemiluminescence immunoassay. The intra-assay CV was 2.3% at 4.2 IU/l for LH and 2.9% at 6.9 IU/l for FSH. The LRL of LH was 0.3 IU/l.
Statistical Analyses
Statistical analyses were performed using the computing environment R (https://www.r-project.org/). Sample size determination was not based on power calculations for treatment differences in testosterone because this was a secondary end point. However, a post hoc estimate using Monte Carlo analysis showed that this study had 87% power to detect a 30% baseline adjusted difference in serum testosterone based on 1,000 stratified bootstrap samples.
Sex steroid hormone concentrations and SHBG were log transformed to meet a normal distribution assumption. Pretreatment vs posttreatment hormone values for each treatment group were analyzed using longitudinal Tobit regressions 8 of the log hormone value against the posttreatment indicator. This model takes into account the floor effect caused by the LRLs of the hormone assays.
Between group differences in achieved hormone levels were analyzed by longitudinal Tobit regressions of posttreatment hormone values against a treatment factor (subcapsular orchiectomy or triptorelin). Two models were used for these analyses, including 1) a model adjusted for the baseline values of the modeled hormone only and 2) a best fit model adjusted for baseline values of the modeled hormone and forward selection. The variables included in the model were concurrent values of hormones (excluding the one modeled), age and BMI. The supplementary material shows the final model selections (http://jurology.com/).
Plots of marginal residuals from the Tobit regressions were used to check model assumptions. A likelihood ratio test was used to determine whether both treatments equally resulted in testosterone values less than 20 ng/dl. All tests were 2-sided with statistical significance considered at a ¼ 0.05. All available data were used in analyses.
RESULTS
A total of 58 men were enrolled in study between September 2013 and March 2015 from the Department of Urology, Herlev and Gentofte University Hospital. Figure 1 shows the CONSORT Table 1 lists baseline patient characteristics.
One patient in the subcapsular orchiectomy group withdrew consent after randomization and before attending any study visits. Nine patients were excluded before the 48-week followup visit. Six of the 28 patients (21%) undergoing subcapsular orchiectomy reported postoperative scrotal swelling/ hematoma not requiring surgical or pharmacological intervention. One patient was hospitalized with a postoperative infected scrotal hematoma requiring surgical revision under general anesthesia. One of the 29 patients (3%) reported local muscle pain after the triptorelin injection and 1 experienced transient pain in the hip opposite the site of injection, which was interpreted as a flare phenomenon. Figure 2 shows serum testosterone levels with time. Table 2 lists the results of between group analyses of testosterone, estradiol and adrenal androgens. Serum testosterone adjusted for baseline testosterone, DHEAS and androstenedione was 29% (95% CI 17.2e41.7) lower after triptorelin therapy compared to subcapsular orchiectomy (p <0.001).
All patients achieved nadir testosterone less than 30 ng/dl after 48 weeks of followup. The proportion of patients achieving testosterone levels less than 20 ng/dl was 79% and 97% at 12 weeks (p <0.05), 92% and 90% at 24 weeks (p ¼ 0.73), and 87% and 100% at 48 weeks (p <0.05) in the subcapsular orchiectomy and triptorelin groups, respectively. LH and FSH expectedly increased after subcapsular orchiectomy but they were suppressed by triptorelin. LH levels were below the LRL in the triptorelin group at all visits except in 3 patients at the 24-week visit. One of these patients had a testosterone level that was above the castrate level (greater than 50 ng/dl) at that visit. Testosterone measurement in this patient at 48 weeks was back in the castrate level range. There were no significant differences in treatment effect for estradiol or adrenal androgens over time.
DHEAS, androstenedione, 17-hydroxyprogesterone and estradiol levels significantly decreased in both treatment arms (p <0.001). The supplementary table (http://jurology.com/) shows hormone values at each visit and the hormone level reduction after treatment start. SHBG levels did not change in either treatment group. 
DISCUSSION
To our knowledge this is the first randomized trial reporting lower testosterone levels after LHRH agonist therapy compared to surgical castration (29% reduction, p <0.001). Previous randomized trials comparing LHRH agonists to orchiectomy did not show a difference in the efficacy of serum testosterone suppression. 9, 10 However, the accuracy and precision of the immunoassays used at the time of these trials were insufficient to detect testosterone level differences at castrate range concentrations. Triptorelin was combined with bicalutamide for the first 30 days. Bicalutamide as monotherapy increases serum testosterone but with a 2-month washout period before subsequent measurements this is unlikely to have influenced the results.
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Orchiectomy increases LH and FSH through a lack of negative feedback whereas triptorelin suppresses LH and FSH after an initial increase. LH receptors are present in prostate cancer cells, and the LH-LH receptor signaling pathway has been shown to induce prostate cancer cell proliferation and increase steroidogenic gene expression and subsequent androgen production in vitro. 12, 13 Thus, the differences in testosterone levels could reflect steroid production at the tumor level independent of adrenal and testicular production.
LH suppression has also been hypothesized to decrease adrenal androgen production. This hypothesis originated after the detection of LH receptors in the adrenal cortex.
14 This is intriguing because newer hormonal therapies that target adrenal androgen production through CYP17 inhibition have shown significant survival benefits in men with castrate resistant prostate cancer. 15 However, we could not find a treatment difference in adrenal androgens. In fact, we noted a similar 20% to 60% reduction of so-called adrenal androgens after subcapsular orchiectomy.
Another possible explanation for our results is that testicular tissue is left behind using the subcapsular surgical approach. However, median levels of testosterone in the current study were equivalent to the median testosterone levels of 15 ng/dl using the best available measurements after total orchiectomy reported by Oefelein et al, 16 which suggests that this explanation is not the case. However, a chemiluminescence immunoassay was used to obtain these data and as such the results cannot be directly compared.
The subcapsular approach initially fell out of favor after the report by McDonald and Calams in 1958 showing the presence of Leydig-like cells in the tunica albuginea and epididymis postoperatively. 17 However, the method was reintroduced when subsequent smaller nonrandomized studies with fewer than 80 cases were unable to detect differences in testosterone levels after subcapsular and total orchiectomy. 18, 19 van der Sluis et al also addressed the issue of residual testicular tissue after subcapsular orchiectomy by measuring inhibin B in a cross-sectional study. 7 This showed lower testosterone levels after LHRH agonist therapy than after surgical castration with subcapsular and total bilateral orchiectomy. Inhibin B was undetectable in all treated men and the investigators concluded that differences in serum testosterone were not explained by residual testicular tissue. However, undetectable levels of inhibin B are also possible in cases of retained testosterone production. 20 Therefore, residual Leydig cell function in our opinion cannot be ruled out as an explanatory mechanism for the lower levels of testosterone seen with LHRH agonist treatment.
The clinical implications of varying testosterone and gonadotropin levels need further evaluation. Earlier studies directly comparing orchiectomy with chemical ADT did not show survival differences between the treatment modalities. 9, 21, 22 However, definitive studies comparing surgical and chemical castration are lacking because these earlier trials were underpowered to detect small survival differences. Furthermore, LHRH agonists give rise to surges in testosterone at the end of the duration of a formulation in a small percentage of patients, which may affect cancer control. In our study LH levels were not fully suppressed in 3 of the 29 patients (10%) at 24 weeks and 2 patients did not reach castrate levels of testosterone. This phenomenon appears to diminish with time because we did not detect a testosterone increase in these patients at 48 weeks. In a retrospective study of 73 men on ADT Morote et al observed that breakthrough testosterone values above 32 ng/dl resulted in decreased progression-free survival. 5 In addition, differences in FSH levels could be clinically important. FSH receptors are present in prostate cancer cells 23 and the vasculature of tumors, and they are thought to be involved in tumor angiogenesis and cancer progression. 24 Studies have shown correlations of serum FSH with the pathological stage of prostate cancer 23 and more recently with time to castration resistant prostate cancer in a retrospective analysis. 25 Moreover, a recent population based study using data on 3,295 men with prostate cancer undergoing ADT from the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database compared clinically relevant adverse effects between orchiectomy and LHRH agonist use. 26 In that series LHRH agonist therapy significantly increased the risk of cardiovascular complications, diabetes mellitus and fracture compared to orchiectomy (all p 0.01). Meanwhile, other studies have not revealed an association between ADT and cardiovascular events. 27 Still other studies have shown an increased risk of cardiovascular disease for orchiectomy and LHRH agonist therapy. 28, 29 This suggestive evidence calls for further randomized comparisons of ADT modalities. These trials should include LHRH antagonist therapy, which results in different FSH and LH profiles compared to LHRH agonists and orchiectomy. 30 Some limitations of this study should be addressed. The evaluation of hormonal differences between the treatment modalities was a secondary end point of the trial. However, the highly significant statistical difference in testosterone levels along with the post hoc power analysis showed that this was not a chance finding and the study was sufficiently powered.
Another limitation is that the interassay CV for testosterone was higher in our study than in previous studies, 7 resulting in a relatively high LRL for serum testosterone. This primarily affected testosterone measurements in the triptorelin group because more men on triptorelin reached the LRL of testosterone and as such these men may have had falsely high testosterone levels. Thus, the difference in testosterone levels between subcapsular orchiectomy and triptorelin may be larger than reported.
CONCLUSIONS
Significantly lower levels of testosterone within the castrate range were reached using the LHRH agonist triptorelin vs subcapsular orchiectomy. To our knowledge this is the first randomized study using the accurate method of LC-MS/MS to directly show differences in testosterone production after 2 forms of ADT. Thus, the findings support the hypothesis that different ADT modalities can vary in favorable and adverse clinical effects. Further studies are needed to fully elucidate the clinical implications of these treatment related hormone differences.
